People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...

Parts of New York state faced up to five feet of snow over the last few days and more is coming across the Great Lakes region ...

Shares of Eli Lilly & Co. LLY advanced 1.69% to $813.33 Tuesday, on what proved to be an all-around mixed trading session for ...

Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

We recently compiled a list of the Billionaire Ken Fisher’s Top 15 Stock Picks Heading Into 2025. In this article, we are ...

Artificial intelligence is changing the way industries do business. But executives in the pharmaceutical industry are still ...

Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion ...

Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 505.84% and ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...